<DOC>
	<DOCNO>NCT01368523</DOCNO>
	<brief_summary>The purpose study provide patient imatinib resistant/intolerant chronic myeloid leukemia - blast crisis , accelerate phase chronic phase , previously enrol CAMN107A2109 benefit treatment , access nilotinib ( AMN107 ) Poland time treatment drug finance National Health Found Poland ( via 'therapeutic program ' ) period 18 month , whichever come first .</brief_summary>
	<brief_title>Study Oral AMN107 ( Nilotinib ) Adult Patients With Imatinib - Resistant - Intolerant Chronic Myeloid Leukemia Blast Crisis , Accelerated Phase Chronic Phase Previously Enrolled CAMN107A2109 Trial</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Imatinib resistant intolerant Philadelphia chromosomepositive CML chronic phase , accelerate phase blast crisis patient previously enrol CAMN107A2109 trial Poland continue treatment nilotinib time enrollment trial . 2 . In opinion investigator would benefit treatment nilotinib 3 . No evidence extramedullary leukaemic involvement , exception liver spleen 4 . Males females ≥18 year age 5. WHO Performance Status ≤ 2 6 . QTc ≤ 450 msec average three serial baseline ECG ( use QTcF formula ) . 7 . Patients must follow laboratory value : Potassium within normal limit correct within normal limit supplement prior first dose study medication Total calcium ( correct serum albumin ) within normal limit correctable supplement Magnesium within normal limit correct within normal limit supplement prior first dose study medication Phosphorus ≥ LLN correctable supplement ALT AST ≤ 2.5 x ULN ≤ 5.0 x ULN consider due tumour Alkaline phosphatase ≤ 2.5 x ULN unless consider due tumour Serum bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 50 ml/min Serum amylase ≤ 1.5 x ULN serum lipase ≤ 1.5 x ULN 8 . Written sign date informed consent prior study procedure perform . 1 . Known T315I mutation 2 . Impaired cardiac function include one following : LVEF &lt; 45 % institutional low limit normal range ( whichever high ) determine echocardiogram Inability determine QT interval ECG Complete leave bundle branch block Use ventricularpaced pacemaker Congenital long QT syndrome know family history long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest brachycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec average three serial baseline ECG ( use QTcF formula ) . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc . History clinically document myocardial infarction History unstable angina ( last 12 month ) Other clinically significant heart disease ( e.g . congestive heart failure uncontrolled hypertension ) . 3 . Known cytopathologically confirm CNS infiltration ( absence suspicion CNS involvement , lumbar puncture require ) 4 . Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , active uncontrolled infection ) 5 . History significant congenital acquire bleed disorder unrelated cancer 6 . Previous radiotherapy ≥ 25 % bone marrow 7 . Major surgery within 4 week prior Day 1 study recover prior surgery 8 . History noncompliance medical regimen inability grant consent 9 . Use therapeutic coumarin derivative ( i.e. , warfarin , acenocoumarol , phenprocoumon ) 10 . Patients actively receive therapy strong CYP3A4 inhibitor ( e.g , erythromycin , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , ritonavir , mibefradil ) treatment either discontinue switched different medication prior start study drug within 5 halflives last dose medication prior start study drug . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>chronic phase</keyword>
	<keyword>accelerate phase</keyword>
	<keyword>blastic phase</keyword>
	<keyword>nilotinib</keyword>
</DOC>